Epidemiology & Biostatistics
The Sohrab Shah Lab
The Shah lab focuses on the major topics of cancer evolution, single cell genomics and transcriptomics, mutational processes and prediction of drug response. We are interested in the major questions which underpin the cellular dynamics of cancer. Why do some cancer patients respond to treatment, while others succumb to their disease? Why are some treatments effective initially, but fail over time? How do cancer cells acquire the ability to spread from one part of the body to another? These are the fundamental yet unresolved questions which limit our understanding of cancer progression. Viewing cancer progression through the lens of evolution, our approach centers on studying cancer cells as fundamental units of information encoding biological properties that evolve in different contexts. At Memorial Sloan Kettering we are leveraging single cell technologies and cellular imaging combined with development and deployment of state of the art machine learning tools to study the cellular dynamics of cancer in patients before, during and after treatment. Our work cross cuts basic and translational science including technology and computational methods development with application to biological and clinical problems in ovarian and breast cancer.
Vázquez-García I, Uhlitz F, Ceglia N, Lim JLP, Wu M, Mohibullah N, Niyazov J, Ruiz AEB, Boehm KM, Bojilova V, Fong CJ, Funnell T, Grewal D, Havasov E, Leung S, Pasha A, Patel DM, Pourmaleki M, Rusk N, Shi H, Vanguri R, Williams MJ, Zhang AW, Broach V, Chi DS, Da Cruz Paula A, Gardner GJ, Kim SH, Lennon M, Long Roche K, Sonoda Y, Zivanovic O, Kundra R, Viale A, Derakhshan FN, Geneslaw L, Issa Bhaloo S, Maroldi A, Nunez R, Pareja F, Stylianou A, Vahdatinia M, Bykov Y, Grisham RN, Liu YL, Lakhman Y, Nikolovski I, Kelly D, Gao J, Schietinger A, Hollmann TJ, Bakhoum SF, Soslow RA, Ellenson LH, Abu-Rustum NR, Aghajanian C, Friedman CF, McPherson A, Weigelt B, Zamarin D, Shah SP. Ovarian cancer mutational processes drive site-specific immune evasion Nature. 2022 612(7941):778-786. PMID: 36517593; PMCID: PMC9771812.
Funnell T, O’Flanagan CH, Williams MJ, McPherson A, McKinney S, Kabeer F, Lee H, Salehi S, Vázquez-García I, Shi H, Leventhal E, Masud T, Eirew P, Yap D, Zhang AW, Lim JLP, Wang B, Brimhall J, Biele J, Ting J, Au V, Van Vliet M, Liu YF, Beatty S, Lai D, Pham J, Grewal D, Abrams D, Havasov E, Leung S, Bojilova V, Moore RA, Rusk N, Uhlitz F, Ceglia N, Weiner AC, Zaikova E, Douglas JM, Zamarin D, Weigelt B, Kim SH, Da Cruz Paula A, Reis-Filho JS, Martin SD, Li Y, Xu H, de Algara TR, Lee SR, Llanos VC, Huntsman DG, McAlpine JN; IMAXT Consortium; Shah SP, Aparicio S. Single-cell genomic variation induced by mutational processes in cancer. Nature. 2022 612(7938):106-115. PMID: 36289342; PMCID: PMC9712114.
Sohrab Shah, PhD
- The Shah Lab studies cancer evolution and response to treatment through high density genomics coupled with advanced computational methods such as machine learning and Bayesian statistical models.
- PhD, University of British Columbia (Canada)
- Susan B Komen Scholar (2018)
- Clarivate Analytics Highly Cited Researchers (2018)
To learn more about available postdoctoral opportunities, please visit our Career Center
To learn more about compensation and benefits for postdoctoral researchers at MSK, please visit Resources for Postdocs
Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.
MSK requires doctors and faculty members to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.
Sohrab Shah discloses the following relationships and financial interests:
Professional Services and Activities
Imagia Canexia Health Inc.
The information published here is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.
This page and data include information for a specific MSK annual disclosure period (January 1, 2022 through disclosure submission in spring 2023). This data reflects interests that may or may not still exist. This data is updated annually.